<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26186664</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier.</ArticleTitle><Pagination><StartPage>2414</StartPage><EndPage>2424</EndPage><MedlinePgn>2414-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1052918</ELocationID><Abstract><AbstractText>This study introduces a new approach for enhancing immunity toward mucosal vaccines. HEV71 killed vaccine that is formulated with nanosize calcium phosphate adjuvant and encapsulated onto chitosan and alginate delivery carriers was examined for eliciting antibody responses in serum and saliva collected at weeks 0, 1, 3, 5, 7 and 9 for viral-specific IgA &amp; IgG levels and viral neutralizing antibody titers. The antibody responses induced in rabbits by the different formulations delivered by a single (buccal) route were compared to those of dual immunization (intradermal / mucosal) and un-immunized control. Chitosan-loaded vaccine adjuvant induced elevated IgA antibody, while Alginate-adjuvant irreversible bonding sequestered the vaccine and markedly reduced immunogenicity. The induced mucosal and parenteral antibody profiles appeared in an inverse manner of enhanced mucosal IgA antibody accompanied by lower systemic IgG following a single oral immunization route. The combined intradermal and oral dual-immunized group developed an elevated salivary IgA, systemic IgG, and virus neutralizing response. A reduced salivary neutralizing antibody titer was observed and attributed to the continual secretion exchanges in saliva. Designing a successful mucosal delivery formulation needs to take into account the vaccine delivery site, dosage, adjuvant and carrier particle size, charge, and the reversibility of component interactions. The dual immunization seems superior and is a important approach for modulating the antibody response and boosting mucosal protection against HEV71 and similar pathogens based on their transmission mode, tissue tropism and shedding sites. Finally, the study has highlighted the significant role of dual immunization for simultaneous inducing and modulating the systemic and mucosal immune responses to EV71.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saeed</LastName><ForeName>Mohamed I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>a Medical Faculty; Microbiology &amp; Parasitology; University of Putra Malaysia ; Serdang , Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omar</LastName><ForeName>Abdul Rahman</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>b Institute of Biosciences; University of Putra Malaysia ; Serdang , Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Mohd Z</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>c Institute of Advanced Technology; University of Putra Malaysia ; Serdang , Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkhidir</LastName><ForeName>Isam M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>d Faculty of Medicine; Microbiology &amp; Parasitology Department ; University of Khartoum ; Khartoum , Sudan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sekawi</LastName><ForeName>Zamberi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>a Medical Faculty; Microbiology &amp; Parasitology; University of Putra Malaysia ; Serdang , Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002130">Calcium Phosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9012-76-4</RegistryNumber><NameOfSubstance UI="D048271">Chitosan</NameOfSubstance></Chemical><Chemical><RegistryNumber>97Z1WI3NDX</RegistryNumber><NameOfSubstance UI="C020243">calcium phosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058956" MajorTopicYN="N">Administration, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002130" MajorTopicYN="N">Calcium Phosphates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048271" MajorTopicYN="N">Chitosan</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007271" MajorTopicYN="N">Injections, Intradermal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044967" MajorTopicYN="N">Serum</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CaP-adjuvant</Keyword><Keyword MajorTopicYN="N">Enterovirus-71</Keyword><Keyword MajorTopicYN="N">IgA-antibody</Keyword><Keyword MajorTopicYN="N">chitosan-carrier</Keyword><Keyword MajorTopicYN="N">dual-delivery</Keyword><Keyword MajorTopicYN="N">mucosal-vaccine</Keyword><Keyword MajorTopicYN="N">nanoparticles</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26186664</ArticleId><ArticleId IdType="pmc">PMC4635880</ArticleId><ArticleId IdType="doi">10.1080/21645515.2015.1052918</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6(2):148-58; PMID:16491139; http://dx.doi.org/10.1038/nri1777</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1777</ArticleId><ArticleId IdType="pubmed">16491139</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464(7286):217-23; PMID:20220840</Citation><ArticleIdList><ArticleId IdType="pubmed">20220840</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45-53; PMID:15812489; http://dx.doi.org/10.1038/nm1213</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1213</ArticleId><ArticleId IdType="pubmed">15812489</ArticleId></ArticleIdList></Reference><Reference><Citation>McGhee JR, Kiyono H. New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis 1993; 2(2):55-73; PMID:8162356</Citation><ArticleIdList><ArticleId IdType="pubmed">8162356</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA. Circulating vaccine-derived Polioviruses: current state of knowledge. Bull World Health Organ 2004; 82(1):16-23; PMID:15106296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585883</ArticleId><ArticleId IdType="pubmed">15106296</ArticleId></ArticleIdList></Reference><Reference><Citation>Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991; 163(1):1-6; PMID:1845806; http://dx.doi.org/10.1093/infdis/163.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/163.1.1</ArticleId><ArticleId IdType="pubmed">1845806</ArticleId></ArticleIdList></Reference><Reference><Citation>Baqar S, Bourgeois AL, Schultheiss PJ, Walker RI, Rollins DM, Haberberger RL, Pavlovskis OR. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine 1995; 13(1): 22-8; PMID:7539199; http://dx.doi.org/10.1016/0264-410X(95)80006-Y</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(95)80006-Y</ArticleId><ArticleId IdType="pubmed">7539199</ArticleId></ArticleIdList></Reference><Reference><Citation>McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10(2):75-88; PMID:1539467; http://dx.doi.org/10.1016/0264-410X(92)90021-B</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(92)90021-B</ArticleId><ArticleId IdType="pubmed">1539467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan EJ, Daly LM, Mills KH. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 2001; 19(8):293-304; PMID:11451471; http://dx.doi.org/10.1016/S0167-7799(01)01670-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-7799(01)01670-5</ArticleId><ArticleId IdType="pubmed">11451471</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82(5): 488-96; PMID:15479434; http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0818-9641.2004.01272.x</ArticleId><ArticleId IdType="pubmed">15479434</ArticleId></ArticleIdList></Reference><Reference><Citation>Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Zangwill K. The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenzavirus vaccine in children. N Engl J Med 1998; 338(20):1405-12; PMID:9580647; http://dx.doi.org/10.1056/NEJM199805143382002</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199805143382002</ArticleId><ArticleId IdType="pubmed">9580647</ArticleId></ArticleIdList></Reference><Reference><Citation>Van dr Lubben I, Verhoef J, Borchard G, Junginger H. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001; 52(2):139-44; PMID:11718937; http://dx.doi.org/10.1016/S0169-409X(01)00197-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(01)00197-1</ArticleId><ArticleId IdType="pubmed">11718937</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against Influenza A virus infection in mice. Vaccine 2003; 21(23):3212-8; PMID:12804850; http://dx.doi.org/10.1016/S0264-410X(03)00234-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(03)00234-2</ArticleId><ArticleId IdType="pubmed">12804850</ArticleId></ArticleIdList></Reference><Reference><Citation>Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Roden RB. Protection against heterologous Human Papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci 2008; 105(15):5850-5; PMID:18413606; http://dx.doi.org/10.1073/pnas.0800868105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0800868105</ArticleId><ArticleId IdType="pmc">PMC2299222</ArticleId><ArticleId IdType="pubmed">18413606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson LB, Norton EB, Clements JD. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011; 23(3):414-20; PMID:21511452; http://dx.doi.org/10.1016/j.coi.2011.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2011.03.009</ArticleId><ArticleId IdType="pubmed">21511452</ArticleId></ArticleIdList></Reference><Reference><Citation>Caputo A, Sparnacci K, Ensoli B, Tondelli L. Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. Curr Drug Deliv 2008; 5(4):230-42; PMID:18855591; http://dx.doi.org/10.2174/156720108785914961</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720108785914961</ArticleId><ArticleId IdType="pubmed">18855591</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999; 17(11):1075-81; PMID:10545912; http://dx.doi.org/10.1038/15058</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/15058</ArticleId><ArticleId IdType="pubmed">10545912</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar J, Rodriguez E. Vaccine adjuvants revisited. Vaccine 2007; 25(19):3752-62; PMID:17336431; http://dx.doi.org/10.1016/j.vaccine.2007.01.111</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.01.111</ArticleId><ArticleId IdType="pubmed">17336431</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg NK, Mangal S, Khambete H, Tyagi RK. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 2010; 4(2):114-28; PMID:20380624; http://dx.doi.org/10.2174/187221110791185015</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187221110791185015</ArticleId><ArticleId IdType="pubmed">20380624</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 1998; 34(2):305-20; PMID:10837683; http://dx.doi.org/10.1016/S0169-409X(98)00045-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(98)00045-3</ArticleId><ArticleId IdType="pubmed">10837683</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>